Table 2.
Odds ratios (OR) and 95% confidence intervals (CI) for the association between anti-EBV antibody level and Burkitt lymphoma (BL) in Ghanaian children
| EBV Protein and Array sequence a | t-test P | BL Mean (SD) | Control Mean (SD) | BL Positivity | Control Positivity | OR tertile 2 (95% CI) b | OR tertile 3 (95% CI) | P-trend |
|---|---|---|---|---|---|---|---|---|
| BMRF1 (EA(D)_p47) YP_001129454.1-67745-68959 | <0.0001 | 1.27 (0.39) | 0.92 (0.21) | 69.3% | 32.0% | 1.80 (0.85, 3.82) | 7.03 (3.58, 13.8) | <0.0001 |
| BMRF1 (EA(D)_p47) AFY97929.1-67486-68700 | <0.0001 | 1.26 (0.39) | 0.93 (0.20) | 68.7% | 33.3% | 2.03 (0.98, 4.19) | 6.79 (3.49, 13.2) | <0.0001 |
| BBLF1 (Tegument protein) YP_001129480.1-109516-109289 | <0.0001 | 1.31 (0.29) | 1.12 (0.23) | 87.3% | 70.7% | 1.36 (0.67, 2.76) | 5.64 (2.98, 10.7) | <0.0001 |
| BHRF1 (Bcl-2 homolog) YP_001129442.1-42204-42779 | <0.0001 | 1.18 (0.31) | 0.90 (0.18) | 68.7% | 24.0% | 0.70 (0.32, 1.49) | 4.96 (2.71, 9.08) | <0.0001 |
| BBLF1 (Tegument protein) AFY97956.1-108555-108328 | <0.0001 | 1.27 (0.29) | 1.08 (0.24) | 85.3% | 64.7% | 1.76 (0.90, 3.47) | 4.79 (2.54, 9.01) | <0.0001 |
| BZLF1 (Zebra [Zta]) CAA24861.1-102338-102210 | <0.0001 | 1.09 (0.36) | 0.87 (0.21) | 44.0% | 15.3% | 1.86 (0.94, 3.68) | 4.46 (2.41, 8.28) | <0.0001 |
| BILF2 (glycoprotein) YP_001129503.1-139063-138317 | <0.0001 | 1.16 (0.28) | 0.98 (0.22) | 72.7% | 46.0% | 1.94 (1.00, 3.77) | 4.44 (2.37, 8.31) | <0.0001 |
| BLRF2 (viral capsid antigen [VCA]_p23) YP_001129461.1-76771-77259 | <0.0001 | 1.48 (0.33) | 1.31 (0.28) | 92.0% | 86.0% | 1.80 (0.92, 3.53) | 4.27 (2.32, 7.89) | <0.0001 |
| BDLF4 (late lytic-cycle regulator) YP_001129488.1-117560-116883 | <0.0001 | 1.24 (0.28) | 1.10 (0.20) | 84.7% | 65.3% | 1.86 (0.96, 3.61) | 4.13 (2.23, 7.63) | <0.0001 |
| BFRF3 (VCA_p18) CAA24838.1-61507-62037 | <0.0001 | 1.54 (0.31) | 1.39 (0.25) | 92.7% | 94.0% | 1.04 (0.53, 2.05) | 4.01 (2.21, 7.28) | <0.0001 |
| BZLF2 (glycoprotein [gp]42) YP_001129466.1-90630-89959 | <0.0001 | 1.36 (0.23) | 1.26 (0.19) | 96.0% | 94.7% | 1.83 (0.95, 3.50) | 3.66 (2.00, 6.72) | <0.0001 |
| BDLF3 (glycoprotein 150) AFY97964.1-118644-117940 | <0.0001 | 1.26 (0.29) | 1.09 (0.26) | 80.7% | 60.7% | 1.87 (0.99, 3.55) | 3.50 (1.91, 6.41) | <0.0001 |
| BBRF3 (glycoprotein M) YP_001129479.1-107679-108896 | <0.0001 | 1.08 (0.28) | 0.94 (0.18) | 60.0% | 36.7% | 1.69 (0.89, 3.22) | 3.42 (1.88, 6.22) | <0.0001 |
| BDLF3 (glycoprotein 150) YP_001129490.1-119605-118901 | <0.0001 | 1.20 (0.34) | 0.99 (0.26) | 72.7% | 52.7% | 1.30 (0.68, 2.48) | 3.35 (1.86, 6.04) | <0.0001 |
| BZLF1 (Zebra [Zta]) YP_001129467.1-90855-90724 | <0.0001 | 1.11 (0.36) | 0.90 (0.21) | 48.0% | 20.0% | 1.24 (0.66, 2.33) | 2.77 (1.55, 4.93) | 0.0003 |
| BALF2 (EA(D)_p138) c YP_001129510.1-165796-162410-1 | <0.0001 | 0.95 (0.21) | 0.83 (0.15) | 38.7% | 11.3% | 1.09 (0.58, 2.05) | 2.69 (1.52, 4.76) | 0.0003 |
| BPFL1 d CAA24839.1-71527-62078-2 | <0.0001 | 1.25 (0.34) | 1.10 (0.21) | 78.0% | 66.0% | 1.09 (0.58, 2.03) | 2.66 (1.50, 4.72) | 0.0004 |
| BPFL1 YP_001129449.1-59370-49906-3 | <0.0001 | 0.97 (0.21) | 0.88 (0.16) | 33.3% | 19.3% | 1.50 (0.81, 2.77) | 2.66 (1.48, 4.75) | 0.0008 |
| Latent membrane protein [LMP] 1 AFY97906.1-168167-168081 | <0.0001 | 1.16 (0.17) | 1.08 (0.15) | 84.0% | 70.0% | 1.88 (1.01, 3.47) | 2.63 (1.45, 4.77) | 0.0017 |
| BPFL1 YP_001129449.1-59370-49906-2 | <0.0001 | 1.04 (0.24) | 0.92 (0.18) | 46.7% | 31.3% | 1.73 (0.94, 3.19) | 2.57 (1.42, 4.64) | 0.0019 |
| Epstein-Barr nuclear antigen [EBNA] 3B YP_001129464.1-83074-83430 | <0.0001 | 1.01 (0.29) | 0.87 (0.24) | 44.7% | 23.3% | 1.03 (0.55, 1.92) | 2.51 (1.42, 4.45) | 0.0007 |
| BVRF2 (VCAp40) YP_001129501.1-136465-138282 | <0.0001 | 1.01 (0.26) | 0.88 (0.17) | 42.7% | 20.0% | 1.18 (0.63, 2.19) | 2.41 (1.37, 4.24) | 0.0014 |
| BDLF2 (glycoprotein that binds BMRF2) YP_001129491.1-120928-119666 | <0.0001 | 1.09 (0.25) | 0.98 (0.17) | 57.3% | 40.0% | 1.01 (0.55, 1.86) | 2.34 (1.33, 4.12) | 0.0019 |
| BcLF1 (VCA_p160) CAA24794.1-137466-133321-1 | <0.0001 | 0.88 (0.26) | 0.77 (0.19) | 23.3% | 12.7% | 1.29 (0.71, 2.36) | 2.24 (1.26, 3.97) | 0.0046 |
| BcLF1 (VCA_p160) AFY97965.1-125044-120899-1 | <0.0001 | 0.88 (0.28) | 0.76 (0.20) | 30.7% | 9.3% | 1.26 (0.69, 2.29) | 2.17 (1.23, 3.82) | 0.0061 |
| BLLF1 (gp350) YP_001129462.1-79936-77276 | <0.0001 | 1.02 (0.25) | 0.91 (0.21) | 45.3% | 30.0% | 1.17 (0.64, 2.17) | 2.09 (1.19, 3.68) | 0.0076 |
| EBNA3A AFY97915.1-80252-82747 | <0.0001 | 1.21 (0.30) | 1.08 (0.20) | 76.0% | 69.3% | 1.13 (0.62, 2.06) | 1.99 (1.13, 3.49) | 0.0139 |
| BALF2 (EA(D)_p138) YP_001129510.1-165796-162410-2 | <0.0001 | 1.02 (0.29) | 0.90 (0.16) | 39.3% | 22.0% | 1.17 (0.64, 2.13) | 1.92 (1.09, 3.35) | 0.0188 |
| BdRF1 (VCA_p40) AFY97974.1-136284-137321 | <0.0001 | 0.82 (0.29) | 0.72 (0.16) | 15.3% | 4.7% | 0.80 (0.44, 1.46) | 1.67 (0.97, 2.89) | 0.049 |
| BFRF3 (VCA_p18) YP_001129448.1-49335-49865 | 0.0002 | 1.56 (0.31) | 1.44 (0.25) | 92.7% | 94.6% | 0.88 (0.45, 1.75) | 3.71 (2.07, 6.67) | <0.0001 |
| BFRF1 (viral egress protein) YP_001129446.1-46719-47729 | 0.0002 | 0.88 (0.23) | 0.79 (0.15) | 14.0% | 6.7% | 1.45 (0.79, 2.69) | 2.51 (1.41, 4.47) | 0.0014 |
| BSLF2/BMLF1 (lytic switch protein) YP_001129456.1-71967-70589 | 0.0002 | 0.88 (0.21) | 0.80 (0.15) | 20.0% | 8.0% | 1.51 (0.83, 2.74) | 2.14 (1.20, 3.82) | 0.0101 |
| BRRF2 (promotes viral progeny) AFY97943.1-93884-95497 | 0.0003 | 1.24 (0.28) | 1.13 (0.25) | 82.0% | 72.7% | 1.31 (0.71, 2.41) | 2.41 (1.36, 4.39) | 0.002 |
a
Table is ordered by (1) t-test p-value (lowest to highest) and (2) OR tertile 3 (highest to lowest).
b
The odds of being a BL case were calculated from a regression model that included age, sex, year of blood draw, and a 3-level variable (tertiles) for anti-EBV antibody level. The tertiles were calculated using the underlying antibody distribution among disease-free controls. All odds ratios are expressed relative to the referent group of tertile 1 (lowest third of antibody distribution).
c
single-stranded[ss] DNA binding protein
d
lytic-cycle protein involved in immune evasion